Jacobs Levy Equity Management’s Cytek Biosciences CTKB Stock Holding History

Jacobs Levy Equity Management’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07M	Sell	241,581 -15,711	-6%	-$67.1K	﹤0.01%	695
2026 Q1	$1.12M	Sell	257,292 -6,885	-3%	-$32.5K	﹤0.01%	686
2025 Q4	$1.33M	Sell	264,177 -560,259	-68%	-$2.6M	0.01%	642
2025 Q3	$2.86M	Sell	824,436 -63,903	-7%	-$240K	0.01%	521
2025 Q2	$3.02M	Buy	888,339 +179,857	+25%	+$599K	0.01%	551
2025 Q1	$2.84M	Buy	+708,482	New	+$3.67M	0.01%	580
2024 Q4	–	Sell	-182,713	Closed	-$1.01M	–	957
2024 Q3	$1.01M	Buy	+182,713	New	+$1.04M	﹤0.01%	720

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jacobs Levy Equity Management's CTKB Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Cytek Biosciences (CTKB) stake by 6.1% in Q2 2026, selling an estimated $67.1K and leaving 241,581 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #695.

Jacobs Levy Equity Management first reported a position in CTKB in Q3 2024 and has held it in 7 quarters since. The position peaked at $3.02M in Q2 2025. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Jacobs Levy Equity Management held 241,581 shares of Cytek Biosciences worth $1.07M as of Q2 2026.
Jacobs Levy Equity Management sold 15,711 Cytek Biosciences shares in Q2 2026, an estimated $67.1K.
Cytek Biosciences made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #695 holding.
Jacobs Levy Equity Management first reported a position in Cytek Biosciences in Q3 2024 and has held it in 7 quarters since.
Jacobs Levy Equity Management's Cytek Biosciences position peaked at $3.02M in Q2 2025.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.